2000 - Study of Drug Resistance mechanisms on Cancer Chemotherapy
1992 - 薬物代謝
1992 - Drug metabolism.
論文 (19件):
Yuichiro Takeda, Naoki Ishizuka, Kazumi Sano, Satoshi Hirano, Manabu Suzuki, Go Naka, Haruhito Sugiyama. Phase I/II Study of Erlotinib to Determine the Optimal Dose in Patients With Non-Small Cell Lung Cancer Harboring Only EGFR Mutations. Clinical and translational science. 2020. 13. 6. 1150-1160
Kazumi Sano, Kazuhiko Nakadate, Kazuhiko Hanada. Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancer. BMC cancer. 2020. 20. 1. 279-279
A. Fukushima, K. Motoshima, M. Shimada, T. Kitazaki, M. Fukuda, K. Hashiguchi, S. Nagashima, K. Sano, Y. Nakamura, S. Kohno. PHASE II TRIAL OF ERLOTINIB IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER HARBORING EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS: ADDITIVE ANALYSIS OF PHARMACOKINETICS OF ERLOTINIB. RESPIROLOGY. 2012. 17. 81-81